Sigilon Therapeutics, Inc. Common Stock
SGTX
SGTX was delisted on the 10th of August, 2023.
48 hedge funds and large institutions have $26.8M invested in Sigilon Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 21 reducing their positions, and 7 closing their positions.
2,100% more call options, than puts
Call options by funds: $44K | Put options by funds: $2K
4% less funds holding
Funds holding: 50 → 48 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
49% less capital invested
Capital invested by funds: $52.2M → $26.8M (-$25.4M)
62% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$269K |
| 2 |
State Street
Boston,
Massachusetts
|
+$119K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$22.3K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$18.8K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$13.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$583K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$394K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$375K |
| 4 |
Millennium Management
New York
|
-$103K |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
-$80K |
SGTX Hedge Fund Activity: Q1 2022 in Review
48 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Sigilon Therapeutics, Inc. Common Stock (SGTX) for Q1 2022, worth a combined $26.8M — down 49% from $52.2M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of SGTX and 5 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 8 added.
The largest buyer was Renaissance Technologies, adding an estimated $269K. The largest seller was Morgan Stanley, cutting an estimated $583K.
- 48 institutional investors held Sigilon Therapeutics, Inc. Common Stock (SGTX) as of Q1 2022, down from 50 in Q4 2021.
- Funds reported $26.8M of Sigilon Therapeutics, Inc. Common Stock stock for Q1 2022, down 49% quarter-over-quarter.
- 5 funds opened new Sigilon Therapeutics, Inc. Common Stock positions in Q1 2022 and 7 closed out, a net change of -2 holders.
- The largest Sigilon Therapeutics, Inc. Common Stock buyer in Q1 2022 was Renaissance Technologies, an estimated $269K added.
- The largest Sigilon Therapeutics, Inc. Common Stock seller in Q1 2022 was Morgan Stanley, an estimated $583K sold.
Based on aggregated 13F filings for Q1 2022.